The invention provides crystalline hydrochloride salts of (S)-3-[(S)-2-methanesulfonyl-1-(4-trifluoromethylphenoxy)ethyl]pyrrolidine. This invention also provides pharmaceutical compositions comprising the crystalline salts, processes and intermediates for preparing the crystalline salts, and methods of using the crystalline salts to treat diseases.
                            该发明提供了(S)-3-[(S)-2-甲磺酰基-1-(4-三
氟甲基苯氧基)乙基]
吡咯烷的结晶盐。该发明还提供了包含这些结晶盐的药物组合物、用于制备这些结晶盐的工艺和中间体,以及利用这些结晶盐治疗疾病的方法。